The foundation for why drug resistance is seen so frequently may be related to the inherent heterogeneity within tumors. Drug resistance is clearly not a single entity, but a multiplicity of entities of which regulation at the cell surface is perhaps only one small part. The multidrug resistance gene complex (MDR) may be the first line of defense against cytotoxic agents, preventing them from remaining inside the cell long enough to inflict damage.
MDR proteins are active membrane transport pumps that efflux exogenous and endogenous substances from cells via calcium-mediated efflux pumps. Overexpression of MDRassociated transport proteins is associated with clinical drug resistance to natural products. Agents that have been demonstrated to interfere with drug efflux include the calcium channel blockers, such as verapamil, and other agents, such as cyclosporin A (CsA) and PSC-833.
A number of phase I/II clinical trials have attempted to modulate MDR-1 expression in acute leukemia. One of the first trials used CsA as an MDR modulator, 1 in combination with high-dose ara-C (HDAC) and daunorubicin in poor risk AML patients. While the complete remission rate was high, response was independent of MDR expression. Increased bilirubin in these patients was interpreted as a surrogate marker for an increase in daunorubicin concentration, leading to the first observation that these agents affect the metabolism of drugs that are hepatically metabolized and excreted. Unfortunately, bile ducts also contain MDR. Similar results have been seen in randomized studies using other MDR modulators.
A recent study that examined escalating doses of daunorubicin and etoposide with PSE-833 demonstrated that multiple mechanisms of resistance probably exist. 2 Patients who did not enter a remission after the first cycle were unlikely to enter remission after the second, even if MDR was inhibited. Further, the dose-limiting toxicities of the drugs were twice as much without PSE-833. Phase III trials and recent results from two cooperative group trials showed no advantage, and perhaps a significant disadvantage, when MDR modulation was combined with chemotherapy. In one study of high risk patients conducted by SWOG, 3 the CR rates were independent of PgP or LRP and the serum daunorubicin levels were increased in the group receiving the modulator, CsA. In an ECOG study of poor risk patients who received MEC therapy with PSC-833, 4 the response rate was higher in the group who did not receive the modulator (28% vs 15%), and the drug levels were similarly decreased in the presence of the modulator. In a CALGB study of newly diagnosed patients over age 60, 2 there was a higher incidence of early death in the PSC-833 arm due to infection and multiorgan failure, and the response rates were again higher in the control group. related to the diversity of transporter mechanisms identified, including MRP, LRP, and BCRP. MRP is a 190 kDa protein whose substrates include the epipodophyllins, anthracyclines, and glutathione-conjugated drugs. LRP is a 110 kDa protein that is a major vault protein localized to the nuclear pore complex; substrates of LRP include the vinca alkaloids, anthracyclines, platinum compounds, and alkylating agents. BCRP is a 72 kDa protein that has homology to the drosophila white gene and is a half-transporter whose substrates include mitoxantrone and topoisomerase I agents. 5 Each of these proteins may play a role in protecting the cell from exogenous toxins.
MDR expression has been shown to correlate with resistance to spontaneous apoptosis in vitro. Studies have demonstrated chemoresistance of the coexpression of at least two cell survival factors, either a combination of drug-resistant molecules with cell survival molecules such as bcl-2, mutant p53, or Hsp p27, or combinations of different MDR based proteins. The coexpression of PgP with MRP has been shown, for instance, to confer anthracycline resistance in vitro and in vivo. 6 A number of mechanisms could be used to overcome MDR. One is prolonged intracellular drug exposure by continuous infusion or high-dose therapy. Drug sequencing may also play a role in minimizing the impact of drug-induced MDR. Since MDR is a normal response to cytotoxic stress, previous exposure to a potentially cytotoxic agent will induce the expression of MDR in the remainder of the population. Finally, the expression of MDR is linked to resistance to caspase-dependent apoptosis, so it may be possible to circumvent that by activating certain caspase-independent pathways.
Several factors limit clinical implementation of MDR modulators. One is the normal expression of MDR on bile duct and kidney. Another is our lack of knowledge of the difference in MDR function, expression, and susceptibility between a normal cell and a leukemic cell. Regulation of MDR gene expression may be part of a cellular 'stress' response and therefore may be a protective mechanism. It is unknown what MDR modulators do to the function of MDR in nonhematopoietic cells or whether MDR proteins are involved in normal mitochondrial transport. Another problem with the agents that were used in previous studies was that they interfered with pharmacokinetics of the other drugs. MDR inhibitors have been shown to decrease the area under the curve (AUC) of a number of agents. AUCs were highly variable among patients and could be used to predict toxicity. In the future, more selective agents may not have these effects. Many of the phase III studies used MDR modulators in the context of patients who were chemorefractory. It may be that the results would be improved in de novo patients who have not developed complementary mechanisms of resistance.
Thus, to date, despite the attractiveness and logic of targeting MDR for therapeutic manipulation, the clinical results have been disappointing. Does this mean that MDR inhibition as a specific target or, more broadly, the global concept of modulating drug resistance mechanisms for therapeutic advantage, is a dead issue? Certainly the concept remains a valid one, but the challenges in translating this concept into clinical application are highly instructive. In this regard, the process of malignant transformation is probably not the result of a single cataclysmic event. Rather, the final product reflects a culmination of multiple genetic and epigenetic mechanisms that conspire to permit the survival and expansion of a highly dysregulated cell cohort. In this context, it is not surprising that modulation of a single mechanism would fail to reverse the complex interplay of factors operative in the malignant clone, particularly when those factors are fundamental to the protection and survival of both normal and malignant cells. It is also not surprising that a mechanism such as MDR represents a pivotal line of defense for multiple cell types. In turn, the ability to modulate such a mechanism in the malignant tissue is limited by the unintended effects on multiple normal cell types.
How do we exploit the diverse mechanisms of drug resistance in ways that target the tumor stem cell selectively and effectively? The burgeoning genomic and proteomic technologies, coupled with an increasing ability to isolate, characterize and manipulate the primordial tumor stem cell will be essential to address this challenge. An intimate understanding of how crucial pathways intersect to promote and sustain the malignant state will help to clarify those critical features that discriminate normalcy from malignancy. Once these key pieces of knowledge are in place, the ability to design drugs with exquisite specificities for crucial targets and a sense of Leukemia how to combine such agents in the clinical setting for maximal tumor cell kill with a great therapeutic index will, in turn, help us to achieve our goals of curing and preventing these devastating malignancies.
